IE
AGN.PRA

Israel Englander’s Allergan plc AGN.PRA Stock Holding History

Israel Englander’s Portfolio AGN.PRA Stock Details AGN.PRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,008
Closed -$857K – 4118
2017
Q1 		$857K Buy
+1,008
New +$835K ﹤0.01% 2492
2016
Q4 		– Sell
-305
Closed -$250K – 3960
2016
Q3 		$250K Buy
+305
New +$264K ﹤0.01% 2894

Other funds holding AGN.PRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
LCM
Lakewood Capital Management New York $1.94B AUM 9.49% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Israel Englander's AGN.PRA Position: Q2 2017 in Review

Israel Englander sold out of Allergan plc (AGN.PRA) in Q2 2017, closing a stake of 1,008 shares — an estimated $857K sold.

Israel Englander first reported a position in AGN.PRA in Q3 2016 and held it in 2 quarters. The position peaked at $857K in Q1 2017. 109 funds tracked by Wall St. Rank hold AGN.PRA as of Q2 2017.

  • Israel Englander reported no remaining Allergan plc position as of Q2 2017 after selling out during the quarter.
  • Israel Englander sold 1,008 Allergan plc shares in Q2 2017, an estimated $857K.
  • Israel Englander first reported a position in Allergan plc in Q3 2016 and held it in 2 quarters.
  • Israel Englander's Allergan plc position peaked at $857K in Q1 2017.
  • 109 funds tracked by Wall St. Rank held Allergan plc as of Q2 2017.

Based on Millennium Management's 13F filing for Q2 2017, filed 14 Aug 2017.